Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

Lupus

Volumn 25, Issue 8, 2016, Pages 925-933

  Nakashima, R ^a   Hosono, Y ^a   Mimori, T ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

anti MDA5 antibody; anti aminoacyl tRNA synthetase antibody; anti synthetase syndrome; clinically amyopathic dermatomyositis; dermatomyositis; enzyme linked immunosorbent assay; ferritin; high resolution computed tomography; interstitial lung disease; Polymyositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE ANTIBODY; AUTOANTIBODY; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AMINO ACID TRANSFER RNA LIGASE; BIOLOGICAL MARKER; IFIH1 PROTEIN, HUMAN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1;

ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; MYOSITIS; MYOSITIS SPECIFIC AUTOANTIBODY; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; BLOOD; COMPLICATION; IMMUNOLOGY; PROCEDURES;

AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; BIOMARKERS; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-INDUCED HELICASE, IFIH1; LUNG DISEASES, INTERSTITIAL;

EID: 84973360084     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316651748     Document Type: Article

References (79)

1. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV,. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 209-215.
2. Reeves WH, Nigam SK, Blobel G,. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 1986; 83: 9507-9511.
3. Targoff IN, Johnson AE, Miller FW,. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361-1370.
4. Targoff IN, Reichlin M,. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28: 796-803.
5. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513-522.
6. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25-28.
7. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-3689.
8. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97-R97.
9. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV,. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 2547-2551.
10. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807-1814.
11. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710-713.
12. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150-157.
13. Ge Y, Lu X, Peng Q, Shu X, Wang G,. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 2015; 10: e0141616-e0141616.
14. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-721.
15. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009; 68: 1621-1625.
16. Muro Y, Sugiura K, Akiyama M,. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 2013; 46: 279-284.
17. Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A,. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 2012; 384: 128-134.
18. Schulte-Pelkum J, Fritzler M, Mahler M,. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009; 8: 632-637.
19. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z,. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38: 973-979.
20. Hozumi H, Enomoto N, Kono M, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One 2015; 10: e0120313-e0120313.
21. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 2014; 53: 2196-2203.
22. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti- MDA5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68: 689-694.
23. Nishikai M, Reichlin M,. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23: 881-888.
24. Mathews MB, Bernstein RM,. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304: 177-179.
25. Mathews MB, Reichlin M, Hughes GR, Bernstein RM,. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160: 420-434.
26. Bunn CC, Bernstein RM, Mathews MB,. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986; 163: 1281-1291.
27. Targoff IN, Trieu EP, Plotz PH, Miller FW,. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35: 821-830.
28. Targoff IN, Trieu EP, Miller FW,. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91: 2556-2564.
29. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 2315-2320.
30. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N,. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46: 1005-1008.
31. Hashish LTE, Sadanandan P, Targoff IN,. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome [abstract]. Arthritis Rheum 2005; 52: S312-S312.
32. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233-241.
33. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 2013; 8: e60442-e60442.
34. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13: 883-891.
35. Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 2014; 9: e85062-e85062.
36. Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 2011; 105: 1238-1247.
37. Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011; 105: 1380-1387.
38. Takato H, Waseda Y, Watanabe S, et al. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia-with or without PM/DM. Respir Med 2013; 107: 128-133.
39. Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73: 227-232.
40. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12: 210-217.
41. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26: 1647-1654.
42. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 2006; 28: 1005-1012.
43. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-1576.
44. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M,. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-2200.
45. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/ MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-440.
46. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T,. Anti- MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-1733.
47. Chen F, Wang D, Shu X, Nakashima R, Wang G,. Anti- MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32: 3909-3915.
48. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012; 51: 1278-1284.
49. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
50. Ceribelli A, Fredi M, Taraborelli M, et al. Prevalence and clinical significance of anti- MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014; 32: 891-897.
51. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. Anti- MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290797-290797.
52. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307-1315.
53. Gono T, Kawaguchi Y, Kuwana M, et al. Brief report: Association of HLA-DRB1∗0101/∗0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64: 3736-3740.
54. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K,. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011; 13: R214-R214.
55. Hosono Y, Nakashima R, Imura Y, et al. The onsets of myositis with myositis-specific autoantibodies (MSAs) are associated with the seasons. Ann Rheum Dis 2013; 72 (Suppl 3): 656-656.
56. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T,. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011; 158: 675-677.
57. Ikeda S, Arita M, Morita M, et al. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti- MDA-5 antibody: to lump or split? BMC Pulm Med 2015; 15: 159-159.
58. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti- MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014; 16: R138-R138.
59. Gono T, Kawaguchi Y, Ozeki E, et al. Serum ferritin correlates with activity of anti- MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 2011; 21: 223-227.
60. Gono T, Sato S, Kawaguchi Y, et al. Anti- MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti- MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51: 1563-1570.
61. Nakashima R, Mimori T,. Anti- MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 2013; 36: 71-76.
62. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 2014; 53: 2196-2203.
63. Horai Y, Koga T, Fujikawa K, et al. Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol 2015; 25: 85-89.
64. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32: 1719-1726.
65. Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000; 39: 428-430.
66. Nakashima R, Hosono Y, Yukawa N, et al. Clinical features and treatment of dermatomyositis patients with anti-CADM-140 (melanoma differentiation-associated protein 5: MDA5) antibody: recommendation of combined immunosuppressive therapy with intensive intravenous cyclophosphamide. Arthritis Rheum 2011; 63: S225-S225.
67. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-105.
68. Bowles NE, Dubowitz V, Sewry CA, Archard LC,. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1987; 1: 1004-1007.
69. Chevrel G, Calvet A, Belin V, Miossec P,. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) 2000; 39: 1037-1039.
70. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM,. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 1986; 29: 1365-1370.
71. Ascherman DP,. Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome. Curr Rheumatol Rep 2015; 17: 56-56.
72. Okiyama N, Sugihara T, Oida T, et al. T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum 2012; 64: 3741-3749.
73. Forman MS, Nakamura M, Mimori T, Gelpi C, Hardin JA,. Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts. Arthritis Rheum 1985; 28: 1356-1361.
74. Ghirardello A, Bendo R, Rampudda ME, Bassi N, Zampieri S, Doria A,. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev 2009; 8: 645-649.
75. Ghirardello A, Rampudda M, Ekholm L, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010; 49: 2370-2374.
76. Targoff IN,. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990; 144: 1737-1743.
77. Quevillon S, Robinson JC, Berthonneau E, Siatecka M, Mirande M,. Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. J Mol Biol 1999; 285: 183-195.
78. Mahler M, Miller FW, Fritzler MJ,. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13: 367-371.
79. Sato S, Kuwana M, Fujita T, Suzuki Y,. Anti-CADM-140/ MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23: 496-502.